Formulary Focus: Cosentyx Navigating Tightly Managed Psoriasis Market
Executive Summary
Payers’ prior authorization and step therapy requirements may delay broad access to Novartis’ Cosentyx until after competition arrives in 2016 from Lilly’s IL-17 inhibitor and possibly from a biosimilar to Humira.